27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Assembly Biosciences Inc (NASDAQ:ASMB) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Madhu Kumar upgraded shares of Assembly Biosciences from Neutral to Buy and reiterated a $42 price target.
The Thesis
The rationale for targeting the Hepatitis B virus' core protein as a multipronged means of disrupting the HBV lifecycle is intriguing, Kumar said in the Monday upgrade note. (See the analyst's track record here.)
Hepatitis B is a life-threatening liver infection.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
In the absence of support for HBV biomarker suppression, Assembly's valuation provides a barrier to optimism on the shares, the analyst said. With the 28-percent decline in the shares since Sept. 28, an effective entry point has been established for investors, he said.
Upcoming HBV core inhibitor Phase 2a from HEC Pharma could provide clinical proof-of-concept for viral biomarker suppression, Kumar said. The data is to be presented at the American Association for the Study of Liver Diseases 2018 meeting in San Francisco Nov. 9-13.
"Beyond AASLD, Phase IIa data for ASMB's lead asset ABI-H0731, guided for [the first half of 2019], could serve as an additional positive catalyst for ASMB shares," the analyst said.
The Price Action
Assembly Biosciences shares have shed 41 percent since the start of the year. The stock was down 2.33 percent at $26.03 at the time of publication Monday.
Related Links:
The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs
Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.